BG106428A - Pharmaceutical compositions for treating psoriasis - Google Patents

Pharmaceutical compositions for treating psoriasis

Info

Publication number
BG106428A
BG106428A BG106428A BG10642802A BG106428A BG 106428 A BG106428 A BG 106428A BG 106428 A BG106428 A BG 106428A BG 10642802 A BG10642802 A BG 10642802A BG 106428 A BG106428 A BG 106428A
Authority
BG
Bulgaria
Prior art keywords
treating psoriasis
pharmaceutical compositions
psoriasis
treating
dextrazoxane
Prior art date
Application number
BG106428A
Other languages
Bulgarian (bg)
English (en)
Inventor
Iervant Zarmanian
Jadranka Rogan-Grgas
Original Assignee
Cyathus Exquirere Pharmaforschungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyathus Exquirere Pharmaforschungs Gmbh filed Critical Cyathus Exquirere Pharmaforschungs Gmbh
Publication of BG106428A publication Critical patent/BG106428A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG106428A 1999-09-10 2002-02-22 Pharmaceutical compositions for treating psoriasis BG106428A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT155899 1999-09-10
US18380600P 2000-02-22 2000-02-22
PCT/EP2000/008879 WO2001019358A2 (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis

Publications (1)

Publication Number Publication Date
BG106428A true BG106428A (en) 2003-04-30

Family

ID=25596169

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106428A BG106428A (en) 1999-09-10 2002-02-22 Pharmaceutical compositions for treating psoriasis

Country Status (16)

Country Link
EP (1) EP1214073A2 (cs)
KR (1) KR20020035131A (cs)
CN (1) CN1378451A (cs)
AU (1) AU7286500A (cs)
BG (1) BG106428A (cs)
BR (1) BR0013921A (cs)
CA (1) CA2384685A1 (cs)
CZ (1) CZ2002729A3 (cs)
EE (1) EE04871B1 (cs)
HR (1) HRPK20020201B1 (cs)
HU (1) HUP0202791A3 (cs)
MX (1) MXPA02002486A (cs)
PL (1) PL354980A1 (cs)
RU (1) RU2002106874A (cs)
SK (1) SK2802002A3 (cs)
WO (1) WO2001019358A2 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053523A1 (en) * 2019-09-18 2021-03-25 Tryp Therapeutics Compositions and methods to improve the therapeutic benefit of bis-dioxopiperazines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234935A (en) * 1967-07-03 1971-06-09 Nat Res Dev Piperazine derivatives
US3941790A (en) * 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
US4963679A (en) * 1988-02-17 1990-10-16 Erbamont, Inc. Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes
JPH09503749A (ja) * 1993-07-23 1997-04-15 エルエックスアール バイオテクノロジー インコーポレイテッド アポトーシスおよび関連した状態の処置方法

Also Published As

Publication number Publication date
WO2001019358A3 (en) 2001-10-04
AU7286500A (en) 2001-04-17
BR0013921A (pt) 2002-05-14
EE04871B1 (et) 2007-08-15
HRP20020201A2 (en) 2003-06-30
CN1378451A (zh) 2002-11-06
SK2802002A3 (en) 2003-02-04
CA2384685A1 (en) 2001-03-22
HUP0202791A3 (en) 2003-02-28
EP1214073A2 (en) 2002-06-19
HUP0202791A2 (hu) 2003-01-28
RU2002106874A (ru) 2003-11-20
KR20020035131A (ko) 2002-05-09
PL354980A1 (en) 2004-03-22
MXPA02002486A (es) 2004-09-10
HRPK20020201B1 (en) 2004-08-31
CZ2002729A3 (cs) 2002-07-17
WO2001019358A2 (en) 2001-03-22
EE200200128A (et) 2003-04-15

Similar Documents

Publication Publication Date Title
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
AP9701041A0 (en) Pyridylpyrrole compounds.
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
SE9802208D0 (sv) Novel compounds
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
CA2176298A1 (en) A single high dose fluoroquinolone treatment
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
BR0211932A (pt) Métodos e composições para administração oral de hormÈnio de paratireóide, pth
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
GB9907571D0 (en) Compounds
AU3598299A (en) Improved compositions for inhalation
SE9802209D0 (sv) Novel compounds
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
BG105204A (en) Salts of paroxetine
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
BG106428A (en) Pharmaceutical compositions for treating psoriasis
AP2001002369A0 (en) Pharmaceutical complex.
YU17002A (sh) Upotreba deksrazoksana u lečenju psorijaze